Dystrophic bladder wall calcifications following intravesical BCG treatment for superficial transitional cell carcinoma of bladder

Joseph E. Spirnak, William L. Lubke, Ian M. Thompson, Milagros Lopez

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Bacillus Calmette-Guerin has been established as one of the most active agents for the treatment of superficial transitional cell carcinoma of the bladder. Although complications do occur with this agent, they are usually transient and mild. Two cases are herein reported in which dystrophic calcification of the urinary bladder occurred following BCG therapy; one had a diffuse and severe complication. This complication can occur with other intravesical agents, and methods for management are reported.

Original languageEnglish (US)
Pages (from-to)89-92
Number of pages4
JournalUrology
Volume42
Issue number1
DOIs
StatePublished - 1993

Fingerprint

Transitional Cell Carcinoma
Mycobacterium bovis
Urinary Bladder
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Dystrophic bladder wall calcifications following intravesical BCG treatment for superficial transitional cell carcinoma of bladder. / Spirnak, Joseph E.; Lubke, William L.; Thompson, Ian M.; Lopez, Milagros.

In: Urology, Vol. 42, No. 1, 1993, p. 89-92.

Research output: Contribution to journalArticle

Spirnak, Joseph E. ; Lubke, William L. ; Thompson, Ian M. ; Lopez, Milagros. / Dystrophic bladder wall calcifications following intravesical BCG treatment for superficial transitional cell carcinoma of bladder. In: Urology. 1993 ; Vol. 42, No. 1. pp. 89-92.
@article{3b3c4d458d3244fa980aff354b0cc127,
title = "Dystrophic bladder wall calcifications following intravesical BCG treatment for superficial transitional cell carcinoma of bladder",
abstract = "Bacillus Calmette-Guerin has been established as one of the most active agents for the treatment of superficial transitional cell carcinoma of the bladder. Although complications do occur with this agent, they are usually transient and mild. Two cases are herein reported in which dystrophic calcification of the urinary bladder occurred following BCG therapy; one had a diffuse and severe complication. This complication can occur with other intravesical agents, and methods for management are reported.",
author = "Spirnak, {Joseph E.} and Lubke, {William L.} and Thompson, {Ian M.} and Milagros Lopez",
year = "1993",
doi = "10.1016/0090-4295(93)90350-J",
language = "English (US)",
volume = "42",
pages = "89--92",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Dystrophic bladder wall calcifications following intravesical BCG treatment for superficial transitional cell carcinoma of bladder

AU - Spirnak, Joseph E.

AU - Lubke, William L.

AU - Thompson, Ian M.

AU - Lopez, Milagros

PY - 1993

Y1 - 1993

N2 - Bacillus Calmette-Guerin has been established as one of the most active agents for the treatment of superficial transitional cell carcinoma of the bladder. Although complications do occur with this agent, they are usually transient and mild. Two cases are herein reported in which dystrophic calcification of the urinary bladder occurred following BCG therapy; one had a diffuse and severe complication. This complication can occur with other intravesical agents, and methods for management are reported.

AB - Bacillus Calmette-Guerin has been established as one of the most active agents for the treatment of superficial transitional cell carcinoma of the bladder. Although complications do occur with this agent, they are usually transient and mild. Two cases are herein reported in which dystrophic calcification of the urinary bladder occurred following BCG therapy; one had a diffuse and severe complication. This complication can occur with other intravesical agents, and methods for management are reported.

UR - http://www.scopus.com/inward/record.url?scp=0027304933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027304933&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(93)90350-J

DO - 10.1016/0090-4295(93)90350-J

M3 - Article

VL - 42

SP - 89

EP - 92

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -